Short-term effects of mineral particle sizes on cellular degradation activity after implantation of injectable calcium phosphate biomaterials and the consequences for bone substitution.
This in vivo study investigated the influence of two calcium phosphate particle sizes (40-80 microm and 200-500 microm) on the cellular degradation activity associated with the bone substitution process of two injectable bone substitutes (IBS). The tested biomaterials were obtained by associating a biphasic calcium phosphate (BCP) ceramic mineral phase and a 3% aqueous solution of a cellulosic polymer (hydroxypropylmethylcellulose). Both were injected into osseous defects at the distal end of rabbit femurs for 2- and 3-week periods. Quantitative results for tartrate-resistant acid phosphatase (TRAP) cellular activity, new bone formation, and ceramic resorption were studied for statistical purposes. Positive TRAP-stained degradation cells were significantly more numerous for IBS 40-80 than IBS 200-500, regardless of implantation time. BCP degradation was quite marked during the first 2 weeks for IBS 40-80, and bone colonization occurred more extensively for IBS 40-80 than for IBS 200-500. The resorption-bone substitution process occurred earlier and faster for IBS 40-80 than IBS 200-500. Both tested IBS displayed similar biological efficiency, with conserved in vivo bioactivity and bone-filling ability. Differences in calcium phosphate particle sizes influenced cellular degradation activity and ceramic resorption but were compatible with efficient bone substitution.
Gauthier
O
O
Equipe INSERM Matériaux d'intérêt Biologique, Faculté de Chirurgie Dentaire, Nantes, France. gauthier@vet-nantes.fr
Bouler
J M
JM
Weiss
P
P
Bosco
J
J
Aguado
E
E
Daculsi
G
G
D000135:Acid Phosphatase / Q000378:metabolism; D000818:Animals; D001672:Biocompatible Materials; D001673:Biodegradation, Environmental; D018786:Bone Substitutes / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D002130:Calcium Phosphates / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D004577:Electron Probe Microanalysis; D005260:Female; D005269:Femur / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D020007:Implants, Experimental; D007267:Injections; D007527:Isoenzymes / Q000378:metabolism; D007785:Lactose / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D008422:Materials Testing; D008747:Methylcellulose / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D008855:Microscopy, Electron, Scanning; D008903:Minerals / Q000378:metabolism*; D016348:Osseointegration / Q000187:drug effects / Q000502:physiology; D010078:Oxazines; D010316:Particle Size; D011817:Rabbits; D000071681:Tartrate-Resistant Acid Phosphatase
D001672:Biocompatible Materials; D018786:Bone Substitutes; D002130:Calcium Phosphates; D007527:Isoenzymes; D008903:Minerals; D010078:Oxazines; C103718:beta-tricalcium phosphate-monocalcium phosphate monohydrate-calcium sulfate hemihydrate mixture; D008747:Methylcellulose; C071191:MK 458; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; D007785:Lactose